“The patients I find that have the most pronounced benefit are the patients with the very large prostates, or the patients who are catheter dependent with concern for neurogenic or myogenic bladder ...

"Just having someone with another set of eyes I think is always helpful and gives you a lot of inspiration as well as a lot of encouragement on exactly what you need to do next," says Gia Ching. In ...

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life ...

Johnson & Johnson seeks FDA approval for TAR-200, targeting BCG-unresponsive high-risk NMIBC with CIS, through the Real-Time Oncology Review program. Phase 2b SunRISe-1 trial data showed an 83.5% ...

The RELIEF ureteral stent is the first FDA-cleared stent for vesicoureteral reflux prevention in the US. The stent's design minimizes bladder spasms and reflux, improving patient comfort compared to ...

Data for newer therapies have shown that more than 50% of patients with BCG-unresponsive NMIBC experience a complete response after just 3 months of treatment. What are your thoughts on these findings ...

Mona Lisa 2.0 receives CE certification, enabling use in 32 European countries for prostate cancer procedures. The platform offers advanced positioning and software for real-time adjustments, ...

"I think integrating microbiome surveillance into clinical trials can bridge the gap between research and also therapeutic applications," says Ilaha Isali, MD, MSc. The abstract suggests that ...

How has the introduction of targeted gene therapy changed the way you approach managing BCG-unresponsive NMIBC? What are the broader implications of using gene therapy to treat BCG-unresponsive NMIBC, ...

"It was a daunting task, although I will say the original core was exceptional, so I had a wonderful framework from which to work," says Jeffrey A. Albaugh, PhD, APRN, CUCNS. In this video, Jeffrey A.

“It's hard for us, based on our evidence here, to say that neoadjuvant chemotherapy is causal in any way or is resulting in prolonged survival,” says Fed Ghali, MD. In this video, Fed Ghali, MD, ...

DART showed safety and efficacy in MIBC, with acceptable toxicity and promising tumor control, comparable to cystectomy outcomes. The RAIDER trial enrolled 345 patients, comparing DART, WBRT, and SART ...